Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions		Total	Total CVS Health Shareholders’ Equity	Common Shares	Treasury Shares		Common Stock and Capital Surplus		Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2023				1,768
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2023	[1]				(480)
Balance at beginning of period at Dec. 31, 2023		$ 76,636	$ 76,461		$ (33,838)	[1]	$ 48,992	[2]	$ 61,604	$ (297)	$ 175
Shareholders' Equity [Roll Forward]
Net income (loss)		1,124	1,113						1,113		11
Other comprehensive income (loss)		(44)	(44)							(44)
Stock option activity, stock awards and other (in shares)				3
Stock option activity, stock awards and other		244	244				244	[2]
Purchases of treasury shares, net of ESPP issuances (in shares)	[1]				(39)
Purchase of treasury shares, net of ESPP issuances		(2,962)	(2,962)		$ (2,935)	[1]	(27)	[2]
Common stock dividends		(844)	(844)						(844)
Other increases (decreases) in noncontrolling interests		(4)	0								(4)
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2024				1,771
Treasury shares outstanding, balance at end of period (in shares) at Mar. 31, 2024	[1]				(519)
Balance at end of period at Mar. 31, 2024		74,150	73,968		$ (36,773)	[1]	49,209	[2]	61,873	(341)	182
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2023				1,768
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2023	[1]				(480)
Balance at beginning of period at Dec. 31, 2023		76,636	76,461		$ (33,838)	[1]	48,992	[2]	61,604	(297)	175
Shareholders' Equity [Roll Forward]
Net income (loss)		2,963
Other comprehensive income (loss)		506
Shares outstanding, balance at end of period (in shares) at Sep. 30, 2024				1,777
Treasury shares outstanding, balance at end of period (in shares) at Sep. 30, 2024	[1]				(519)
Balance at end of period at Sep. 30, 2024		75,106	74,944		$ (36,813)	[1]	49,510	[2]	62,038	209	162
Shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2024				1,771
Treasury shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2024	[1]				(519)
Balance at beginning of period at Mar. 31, 2024		74,150	73,968		$ (36,773)	[1]	49,209	[2]	61,873	(341)	182
Shareholders' Equity [Roll Forward]
Net income (loss)		1,768	1,770						1,770		(2)
Other comprehensive income (loss)		22	22							22
Stock option activity, stock awards and other (in shares)				6
Stock option activity, stock awards and other		159	159				159	[2]
Purchases of treasury shares, net of ESPP issuances (in shares)	[1]				(2)
Purchase of treasury shares, net of ESPP issuances		(143)	(143)		$ (146)	[1]	3	[2]
Common stock dividends		(846)	(846)						(846)
Other increases (decreases) in noncontrolling interests		1	0								1
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2024				1,777
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2024	[1]				(521)
Balance at end of period at Jun. 30, 2024		75,111	74,930		$ (36,919)	[1]	49,371	[2]	62,797	(319)	181
Shareholders' Equity [Roll Forward]
Net income (loss)		71	87						87		(16)
Other comprehensive income (loss)		528	528							528
Stock option activity, stock awards and other		138	138				138	[2]
ESPP issuances, net of purchase of treasury shares (in shares)	[1]				2
ESPP issuances, net of purchase of treasury shares		107	107		$ 106	[1]	1	[2]
Common stock dividends		(846)	(846)						(846)
Other increases (decreases) in noncontrolling interests		(3)	0								(3)
Shares outstanding, balance at end of period (in shares) at Sep. 30, 2024				1,777
Treasury shares outstanding, balance at end of period (in shares) at Sep. 30, 2024	[1]				(519)
Balance at end of period at Sep. 30, 2024		$ 75,106	74,944		$ (36,813)	[1]	49,510	[2]	62,038	209	162
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2024				1,778
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2024		(518)			(518)	[3]
Balance at beginning of period at Dec. 31, 2024		$ 75,730	75,560		$ (36,818)	[3]	49,661	[4]	62,837	(120)	170
Shareholders' Equity [Roll Forward]
Net income (loss)		1,782	1,779						1,779		3
Other comprehensive income (loss)		179	179							179
Stock option activity, stock awards and other (in shares)				1
Stock option activity, stock awards and other		176	176				176	[4]
ESPP issuances, net of purchase of treasury shares (in shares)	[3]				1
ESPP issuances, net of purchase of treasury shares		83	83		$ 83	[3]
Common stock dividends		(848)	(848)						(848)
Other increases (decreases) in noncontrolling interests		8	0								8
Shares outstanding, balance at end of period (in shares) at Mar. 31, 2025				1,779
Treasury shares outstanding, balance at end of period (in shares) at Mar. 31, 2025	[3]				(517)
Balance at end of period at Mar. 31, 2025		$ 77,110	76,929		$ (36,735)	[3]	49,837	[4]	63,768	59	181
Shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2024				1,778
Treasury shares outstanding, balance at beginning of period (in shares) at Dec. 31, 2024		(518)			(518)	[3]
Balance at beginning of period at Dec. 31, 2024		$ 75,730	75,560		$ (36,818)	[3]	49,661	[4]	62,837	(120)	170
Shareholders' Equity [Roll Forward]
Net income (loss)		(1,195)
Other comprehensive income (loss)		$ 536
Shares outstanding, balance at end of period (in shares) at Sep. 30, 2025				1,786
Treasury shares outstanding, balance at end of period (in shares) at Sep. 30, 2025		(516)			(516)	[3]
Balance at end of period at Sep. 30, 2025		$ 73,110	72,928		$ (36,776)	[3]	50,181	[4]	59,107	416	182
Shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2025				1,779
Treasury shares outstanding, balance at beginning of period (in shares) at Mar. 31, 2025	[3]				(517)
Balance at beginning of period at Mar. 31, 2025		77,110	76,929		$ (36,735)	[3]	49,837	[4]	63,768	59	181
Shareholders' Equity [Roll Forward]
Net income (loss)		1,013	1,021						1,021		(8)
Other comprehensive income (loss)		213	213							213
Stock option activity, stock awards and other (in shares)				6
Stock option activity, stock awards and other		183	183				183	[4]
Purchases of treasury shares, net of ESPP issuances (in shares)	[3]				(1)
Purchase of treasury shares, net of ESPP issuances		(114)	(114)		$ (114)	[3]
Common stock dividends		(853)	(853)						(853)
Other increases (decreases) in noncontrolling interests		(1)	0								(1)
Shares outstanding, balance at end of period (in shares) at Jun. 30, 2025				1,785
Treasury shares outstanding, balance at end of period (in shares) at Jun. 30, 2025	[3]				(518)
Balance at end of period at Jun. 30, 2025		77,551	77,379		$ (36,849)	[3]	50,020	[4]	63,936	272	172
Shareholders' Equity [Roll Forward]
Net income (loss)		(3,990)	(3,975)						(3,975)		(15)
Other comprehensive income (loss)		144	144							144
Stock option activity, stock awards and other (in shares)				1
Stock option activity, stock awards and other		161	161				161	[4]
ESPP issuances, net of purchase of treasury shares (in shares)	[3]				2
ESPP issuances, net of purchase of treasury shares		73	73		$ 73	[3]
Common stock dividends		(854)	(854)						(854)
Other increases (decreases) in noncontrolling interests		$ 25	0								25
Shares outstanding, balance at end of period (in shares) at Sep. 30, 2025				1,786
Treasury shares outstanding, balance at end of period (in shares) at Sep. 30, 2025		(516)			(516)	[3]
Balance at end of period at Sep. 30, 2025		$ 73,110	$ 72,928		$ (36,776)	[3]	$ 50,181	[4]	$ 59,107	$ 416	$ 182

[1] Treasury shares include 1 million shares held in trust and treasury stock includes $29 million related to shares held in trust as of September 30, 2024, June 30, 2024, March 31, 2024 and December 31, 2023.

[2] Common stock and capital surplus includes the par value of common stock of $18 million as of September 30, 2024, June 30, 2024, March 31, 2024 and December 31, 2023.

[3] Treasury shares include 1 million shares held in trust and treasury stock includes $29 million related to shares held in trust as of September 30, 2025, June 30, 2025, March 31, 2025 and December 31, 2024.

[4] Common stock and capital surplus includes the par value of common stock of $18 million as of September 30, 2025, June 30, 2025, March 31, 2025 and December 31, 2024.